The stock of Intellia Therapeutics Inc (NASDAQ:NTLA) is a huge mover today! About 470,874 shares traded hands or 36.31% up from the average. Intellia Therapeutics Inc (NASDAQ:NTLA) has risen 6.00% since September 13, 2016 and is uptrending. It has underperformed by 1.52% the S&P500.
The move comes after 5 months positive chart setup for the $455.39 million company. It was reported on Oct, 13 by Barchart.com. We have $19.07 PT which if reached, will make NASDAQ:NTLA worth $191.26M more.
Analysts await Intellia Therapeutics Inc (NASDAQ:NTLA) to report earnings on November, 3. After $-0.36 actual EPS reported by Intellia Therapeutics Inc for the previous quarter, Wall Street now forecasts -41.67% EPS growth.
Intellia Therapeutics Inc (NASDAQ:NTLA) Ratings Coverage
Out of 4 analysts covering Intellia Therapeutics (NASDAQ:NTLA), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Intellia Therapeutics has been the topic of 5 analyst reports since May 31, 2016 according to StockzIntelligence Inc. The company was upgraded on Friday, August 5 by Jefferies. The stock of Intellia Therapeutics Inc (NASDAQ:NTLA) has “Outperform” rating given on Tuesday, May 31 by Credit Suisse. Wedbush initiated the shares of NTLA in a report on Tuesday, May 31 with “Outperform” rating. Jefferies initiated Intellia Therapeutics Inc (NASDAQ:NTLA) rating on Tuesday, May 31. Jefferies has “Hold” rating and $33 price target. The rating was upgraded by Leerink Swann on Friday, August 5 to “Outperform”.
According to Zacks Investment Research, “Intellia Therapeutics, Inc. is a genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. Intellia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.”
More recent Intellia Therapeutics Inc (NASDAQ:NTLA) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on April 16, 2016. Also Globenewswire.com published the news titled: “Intellia Therapeutics to Present at September Investor Healthcare Conferences” on September 01, 2016. Marketwatch.com‘s news article titled: “Intellia Therapeutics trading above issue price in market debut” with publication date: May 06, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.